Dr. Kathryn Dao - "I did not choose rheumatology — it chose me." A rheum profile. https://t.co/TvJrrSGS64 https://t.co/uwVdWmTSK1

Doctor Appointment Wait Times are Up Forbes reports that a recent Merritt Hawkins survey shows that patients are waiting an average of 26 days for a scheduled appointment with a doctor. https://t.co/qYfTf2Kxlv https://t.co/BuvihCk0M6

Spanish SpA Registry (REGISPONSER) - 18.3% had psoriasis; w/ 3/4 of these (76%) having PSO before MSK Sxs. Pts w/ PSO before MSK Sxs had shorter dz duration, lower BMI, Less B27 & anterior uveitis, more dactylitis and ^risk PsA dx (78% vs 56%) https://t.co/sz9nKkDoEX https://t.co/B0TmMqZpoY

Does Methotrexate Use Lead to Melanoma? A systematic review suggests that low-dose methotrexate (MTX) use is associated with an increased melanoma risk, but the absolute risk increase could be considered negligible. https://t.co/aLFBoB7M48 https://t.co/A1sHLaguqy

2022 New ACR Guidance on Glucocorticoid-Induced Osteoporosis (GIOP) The ACR has updated this guideline and includes recommendations on abaloparatide (PTHrP) and romosozumab, which are newly available since the ACR’s 2017 GIOP guideline. https://t.co/byehJlihCY https://t.co/xnKPC1V0l7

Disease Activity Drives Adverse Pregnancy Outcomes in RA Two large RA registries have shown that pregnancy outcomes in rheumatoid arthritis (RA) patients is more related to RA disease activity rather than treatments use to control RA. https://t.co/HtCdjhU5iv https://t.co/FLMjO56xZV

The 2022 ACR abstracts are published and posted for you. Let the Learning begin! https://t.co/fNkzQVXHJx https://t.co/9AuamLB0Ha

A longitudinal study of 506 ANCA-associated vasculitis (AAV) pts showed pts w/ negative ANCA serologies within 180 days of induction had signif lower risk of relapse (HR 0.55; 0.38 to 0.81) but not for ESRD or death within 5 years. https://t.co/qFb2Usov8L https://t.co/faogbabc2W

Immunosuppresive (IST; MMF or AZA) withdrawl in 96 stable Lupus Nephritis pts also on HCQ. After 2 years, Relapse occurred in 12.5% w/ IST continued & 27.3% with IST D/C (Not noninferior). Less Severe SLE flares (renal & extrarenal) w/ IST continuation https://t.co/TM6Ng3vzeS https://t.co/UNBdg1Oh6z

CD19 CAR T Cell Therapy in SLE Dr. Jack Cush reviews the news, journal reports, ACR and FDA announcements from the past week on RheumNow. https://t.co/OJ8WFyB3jc https://t.co/11wanMBjkO

Anti-CD19 CAR T cell therapy for refractory #SLE published in Nature Medicine. 5 pts (22yrs) w/ refractory dz, active SLE (SLEDAI=16). Autologous pt T cells transduced to CD19 CAR Tcells, and lead to remission in 5/5 w/in 3 mos & maintained median 8 mos https://t.co/0epnffCNEN https://t.co/IMRzhOzgei